Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
about
Treatment Resistant HypertensionMineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!Sleep-disordered breathing in heart failure: identifying and treating an important but often unrecognized comorbidity in heart failure patientsThe efficacy of antihypertensive drugs in chronic intermittent hypoxia conditions.Resistant hypertension and untreated severe sleep apnea: slowly gaining insightSleep and hypertension.Resistant hypertension and obstructive sleep apnea: the sparring partnersAldosteronism and resistant hypertension.Common secondary causes of resistant hypertension and rational for treatmentRole of the kidneys in resistant hypertensionEffects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysisRenal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apneaEffect of diuretics and sodium-restricted diet on sleep apnea severity: study protocol for a randomized controlled trialEffects of Heart Failure and its Pharmacological Management on Sleep.Role of obstructive sleep apnea in cardiovascular disease.Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-AnalysisEffects of continuous positive airway pressure therapy on plasma aldosterone levels in patients with obstructive sleep apnea: A meta-analysis.Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronismMeta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system.Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept studyResistant hypertension, obstructive sleep apnoea and aldosterone.Resistant hypertension and obstructive sleep apnea in the setting of kidney diseaseManagement of patients with resistant hypertension: current treatment options.The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial.Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment.Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.Vascular changes, cardiovascular disease and obstructive sleep apnea.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.Recent advancements in the treatment of resistant hypertension.Evaluation and pharmacologic approach to patients with resistant hypertension.Management of hypertension in the elderly.Pharmacotherapy of obstructive sleep apnea.Supine fluid redistribution: should we consider this as an important risk factor for obstructive sleep apnea?Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea.Obstructive sleep apnea and hypertension: is the primary link simply volume overload?Aldosterone receptor antagonists: current perspectives and therapiesThe role of obesity and obstructive sleep apnea in the pathogenesis and treatment of resistant hypertension.Obstructive sleep apnea syndrome and chronic kidney disease: a new cardiorenal risk factor.Obstructive sleep apnea syndrome as a cause of resistant hypertension.
P2860
Q26775459-CBB5973B-69C6-4121-B622-C8FFC5BE2676Q26776149-6FCFC687-09C2-45E4-B898-83892CD1C68FQ28681207-6A6354C4-0194-4271-82C6-CF813557D672Q30428971-547F095F-4272-4E19-BE55-4D85ED615BE8Q33933739-5AAEB9A5-85F8-4174-B04D-B6BC7D4302BDQ34035192-5FE6A4B3-F76B-4AE2-996A-6771A80606EDQ34512680-C5A7773B-59C2-4E04-85F5-A17763DDDA35Q34557307-2B5782CF-C8A7-4F36-A7AE-FDCAB8A373CFQ34669789-CF5E926A-2253-4690-9146-26EC3C11FB06Q34725369-5A01A24E-97DD-4831-BA9D-919BABFE6E23Q34919512-888E0D8B-EF73-4EFB-8C21-34198BAFAA5EQ35321128-C11BB590-15CA-4BDC-8C40-78AF5F2D42C2Q35544844-B02131F2-08AC-455C-AE6D-8D9180EB7BA4Q35572665-E17A490A-25FF-4142-9992-836929ABBC35Q35706912-50F9BD81-FB7E-4028-80EB-41708C9E1FB0Q36072334-2B558D20-8705-45B5-86C8-162BE77C8810Q36165729-461474C7-2223-46E7-B2FB-6AFB636CBFEEQ36740791-2F4D90B2-72A5-450D-B987-1166D41032C7Q37039244-AF9479A3-5A70-4EE6-B69E-FAA5A07F6B37Q37050292-52AC649C-01F2-4C14-8957-9C82BBD53ED3Q37108921-7833BEB6-94B2-47D1-8A4B-90B2531F4294Q37167764-DC8A630E-F80B-4C62-B5EA-5C41EACE0F53Q37304418-EC24E541-B906-4FF1-951F-FF2F0255186EQ37479825-D0B56D7B-2CF3-4D44-A636-A3585E9680B2Q37495691-FC11D3C3-5FC9-4001-97C0-1BBCA954D206Q37811998-2475BFE3-DE2B-4771-8B22-D93A790D6519Q37859758-C098FE16-2A87-4154-996F-25E9B1279062Q37939427-6E200683-A82B-4599-8948-56042D821427Q37976974-2D153DBB-EF71-4F16-A4D0-B5A8236EB713Q37982210-411AACAE-F7DB-4C0B-AB4F-09A73412C1ADQ37982211-1EC51CC6-C97C-4F82-AF32-CA4BCD396D45Q37992922-664486C7-26C5-47CF-97E9-FC2020257EB2Q37994293-B2D84829-4E5D-455F-99DD-6AAB18BE6F9FQ38032789-7D4787AD-DB36-4C35-B1F2-3F81C5233552Q38066462-B84EADD0-7C9A-4F14-BE1D-145C5B9AD34CQ38096919-FA488EDF-F9B1-4823-9A9C-441A034A2750Q38120241-4AD6298C-D31C-4180-988E-816AD40E820AQ38172010-CB7A8C28-816A-4CB3-B2D5-F480C14375DEQ38179027-01A1C104-9510-42C2-B559-5092E3E9B6DDQ38209961-C41F47F7-BC3B-41A7-B6C0-B5A60D8D590D
P2860
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Spironolactone reduces severit ...... tension: a preliminary report.
@ast
Spironolactone reduces severit ...... tension: a preliminary report.
@en
type
label
Spironolactone reduces severit ...... tension: a preliminary report.
@ast
Spironolactone reduces severit ...... tension: a preliminary report.
@en
prefLabel
Spironolactone reduces severit ...... tension: a preliminary report.
@ast
Spironolactone reduces severit ...... tension: a preliminary report.
@en
P2093
P2860
P356
P1476
Spironolactone reduces severit ...... tension: a preliminary report.
@en
P2093
D A Calhoun
S J Thomas
S M Harding
S S Cofield
P2860
P2888
P304
P356
10.1038/JHH.2009.96
P577
2009-12-17T00:00:00Z
P5875
P6179
1044428967